IP Verse

Binding Molecules For Bcma And Cd3 - EP2780375

The patent EP2780375 was granted to Amgen on Sep 11, 2019. The application was originally filed on Nov 15, 2012 under application number EP12805432A. The patent is currently recorded with a legal status of "Revoked".

EP2780375

AMGEN
Application Number
EP12805432A
Filing Date
Nov 15, 2012
Status
Revoked
May 31, 2024
Grant Date
Sep 11, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFIJun 12, 2020HOFFMANN EITLEADMISSIBLE
JAMES POOLEJun 11, 2020CARPMAELS & RANSFORDADMISSIBLE
MATHYS & SQUIREJun 11, 2020MATHYS & SQUIREADMISSIBLE
REGENERON PHARMACEUTICALSJun 11, 2020CARPMAELS & RANSFORDADMISSIBLE
TENEOBIOJun 10, 2020HOFFMANN EITLEWITHDRAWN
PFIZERMay 4, 2020PFIZERWITHDRAWN
JANSSEN BIOTECHApr 14, 2020CARPMAELS & RANSFORDADMISSIBLE
ABBVIEMar 6, 2020KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
ABBVIEMar 6, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (68) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0171496
DESCRIPTIONEP0173494
DESCRIPTIONEP0183070
DESCRIPTIONEP0239400
DESCRIPTIONEP0244234
DESCRIPTIONEP0402226
DESCRIPTIONEP1019141
DESCRIPTIONGB2177096
DESCRIPTIONUS2003070185
DESCRIPTIONUS4485045
DESCRIPTIONUS4544545
DESCRIPTIONUS4816397
DESCRIPTIONUS4816567
DESCRIPTIONUS4946778
DESCRIPTIONUS5013556
DESCRIPTIONUS5223409
DESCRIPTIONUS5225539
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5648260
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5859205
DESCRIPTIONUS6300064
DESCRIPTIONUS6407213
DESCRIPTIONWO0034317
DESCRIPTIONWO02066516
DESCRIPTIONWO2007042261
DESCRIPTIONWO2008119567
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9738731
DESCRIPTIONWO9852976
DESCRIPTIONWO9954440
INTERNATIONAL-SEARCH-REPORTWO0187977
INTERNATIONAL-SEARCH-REPORTWO02066516
INTERNATIONAL-SEARCH-REPORTWO2004106383
INTERNATIONAL-SEARCH-REPORTWO2009132058
INTERNATIONAL-SEARCH-REPORTWO2012066058
OPPOSITIONEP1210425
OPPOSITIONEP1223964
OPPOSITIONEP1806143
OPPOSITIONEP2640750
OPPOSITIONEP2780374
OPPOSITIONUS2007212733
OPPOSITIONUS9150664
OPPOSITIONUS9340621
OPPOSITIONWO0040716
OPPOSITIONWO0112812
OPPOSITIONWO0124811
OPPOSITIONWO0187977
OPPOSITIONWO02066516
OPPOSITIONWO2004106383
OPPOSITIONWO2005040220
OPPOSITIONWO2005061547
OPPOSITIONWO2007042261
OPPOSITIONWO2008119565
OPPOSITIONWO2008119566
OPPOSITIONWO2008119567
OPPOSITIONWO2009132058
OPPOSITIONWO2010037835
OPPOSITIONWO2010037836
OPPOSITIONWO2010037837
OPPOSITIONWO2010037838
OPPOSITIONWO2010104949
OPPOSITIONWO2012066058
OPPOSITIONWO2013072406
OPPOSITIONWO2014072406

Non-Patent Literature (NPL) Citations (83) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "BCMA (Vicky-1): sc-57037", SANTA CRUZ BIOTECHNOLOGY, (20090813), SANTA CRUZ BIOTECHNOLOGY, URL: http://datasheets.scbt.com/sc-57037.pdf, (20200807), XP055720861-
OPPOSITION- Anonymous, "Homo sapiens CD3e molecule (CD3E), mRNA - Nucleotide - NCBI NM_000733", Genbank NM_000733, (20200423), pages 1 - 4, Genbank NM_000733, URL: https://www.ncbi.nlm.nih.gov/nuccore/NM_000733.3, (20201204), XP055756738-
OPPOSITION- Anonymous, "TNFRSF17 - Tumor necrosis factor receptor superfamily member 17 - Homo sapiens (Human) - TNFRSF17 gene & protein", Uniprot Q02223 (TNR17_HUMAN), (20110803), pages 1 - 8, Uniprot Q02223 (TNR17_HUMAN), URL: https://www.uniprot.org/uniprot/Q02223, (20201204), XP055756686-
OPPOSITION- BAEUERLE et al., "BiTE: Teaching antibodies to engage T-cells for cancer therapy", Current Opinion in Molecular Therapeutics, (20090000), vol. 11, no. 1, pages 22 - 30, XP009151509-
OPPOSITION- "BCMA (human) monoclonal antibody (Vicky-1)", ENZO Data Sheet, (20191220), XP055499522-
OPPOSITION- "BCMA (Vicky-1): sc-57037", SANTA CRUZ BIOTECHNOLOGY Data Sheet, (2009), XP055720861-
OPPOSITION- "BCMA (Vicky-1): sc-57037", SANTA CRUZ BIOTECHNOLOGY Datasheet, XP055720861-
OPPOSITION- Bellucci, Et Al, "Complete response to donor lymphocyte infusion in patients with multiple myeloma is associated with antibody response to BCMA, a plasma cell membrane receptor", Blood, (20031116), vol. 102, no. 11, pages 192a - 193a, XP055756724-
OPPOSITION- BELLUCCI et al., "Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma- cell membrane receptor", Blood, (20050515), vol. 105, no. 10, pages 3945 - 3950, XP002581271-
OPPOSITION- BELLUCCI ROBERTO, ET AL, "Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.", BLOOD, US, (20050515), vol. 105, no. 10, ISSN 0006-4971, pages 3945 - 3950, XP002581271-
OPPOSITION- Chames Patrick; Baty Daniel, "Bispecific antibodies for cancer therapy.", Current Opinion in Drug Discovery & Development, Current Drugs Ltd., UK, UK, (20090301), vol. 12, no. 2, ISSN 2040-3437, pages 276 - 283, XP009145632-
OPPOSITION- Chames Patrick; Baty Daniel, "Bispecific antibodies for cancer therapy.", Current Opinion in Drug Discovery & Development, UK, (20090301), vol. 12, no. 2, ISSN 2040-3437, pages 276 - 283, XP009145632-
OPPOSITION- CLAYTON et al., "CD3η and CD3ζ are alternatively spliced products of a common genetic locus and are transcriptionally and/or post-transcriptionally regulated during T-cell development", Proceedings of the National Academy of Sciences USA, (19910600), vol. 88, pages 5202 - 5206, XP055718964-
OPPOSITION- Dafne Müller, Et Al, "Recombinant bispecific antibodies for cancer therapy muller", Handbook of Therapeutic Antibodies, (20110101), pages 235 - 249, XP055756680-
OPPOSITION- Dafne Müller, Kontermann, Roland, "Bispecific antibodies for cancer immunotherapy", Biodrugs, (20100101), vol. 24, no. 2, pages 89 - 98, XP055744248-
OPPOSITION- "equate to", Oxford Advanced Learner's Dictionary, URL: https:/ /www.oxfordlearnersdictionaries.com/definition/americanenglish/equate-to-
OPPOSITION- FITZGERALD et al., The Cytokine FactsBook, (20010000), pages 151 - 152-
OPPOSITION- FRANK, "Specificity and Cross-Reactivity", Immunology and evolution of infectious diseases, (20020000), pages 33 - 56, XP055524479-
OPPOSITION- "Homo sapiens gene for BCMA, complete cds", GenBank, Database accession no. AB052772-
OPPOSITION- "Human BCMA/TNFRSF17 Antibody Catalog Number: MAB193", R&D Systems Data Sheet, (20180702), XP055720877-
OPPOSITION- KEVIN C., Lindquist Declaration and Annexes 1 (D4a) and 2 (D4b) and c.v. (D4c-
OPPOSITION- MÃœLLER et al., "Bisecific antibodies for cancer immunotherapy", Biodrugs, (20100000), vol. 24, no. 2, pages 89 - 98-
OPPOSITION- MÃœLLE R et al., "Recombinant bispecific antibodies for cellular cancer immunotherapy", Current Opinion in Molecular Therapeutics, (20060000), vol. 9, no. 4, pages 319 - 326, XP009169663-
OPPOSITION- NEISIG et al., "Assembly of the T-cell antigen receptor. Participation of the CD3 omega chain", Journal of Immunology, (19930700), vol. 151, pages 870 - 879, XP055718970-
OPPOSITION- PELEKANOU et al., BMC Cancer, (20080000), vol. 8, no. 76, pages 1 - 9, XP021034711-
OPPOSITION- R&D Systems, "Human BCMA/TNFRSF17 Antibody Catalog Number: MAB193", R&D Systems, (20180702), URL: https://resources.rndsystems.com/pdfs/datasheets/mab193.pdf, (20200807), XP055720877-
OPPOSITION- Roberto Bellucci, Et Al, "Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highlv expressed antigens", Blood, (20040115), vol. 103, no. 2, pages 656 - 663, XP055744212-
OPPOSITION- RYAN et al., "Antibody targeting of B- cell maturation antigen on malignant plasma cells", Mol Cancer Ther, (20070000), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN et al., "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Mol Cancer Ther., (20070000), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN et al., "Antibody targeting of B-cell maturation antigen on malignant plasma cells", Molecular Cancer Therapeutics, (20071100), vol. 6, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN et al., Mol Cancer Ther, (20070000), vol. 6, no. 11, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US, (20071101), vol. 6, no. 11, ISSN 1535-7163, pages 3009 - 3018, XP002581270-
OPPOSITION- RYAN MAUREEN C, ET AL, "Antibody targeting of B-cell maturation antigen on malignant plasma cells.", Molecular Cancer Therapeutics, US, (20071101), vol. 6, no. 11, ISSN 1535-7163, pages 3009 - 3018, XP002581270-
OPPOSITION- TARTE KARIN et al, "BAFF IS A SURVIVAL FACTOR FOR MULTIPLE MYELOMA CELLS.ABSTRACT NO 3203", BLOOD, The American Society of Hematology, US, US, (20021201), vol. 100, no. 11, ISSN 0006-4971, page 811a, XP009084045-
OPPOSITION- Thakur Archana; Lum Lawrence G, "Cancer therapy with bispecific antibodies: Clinical experience.", Current opinion in molecular therapeutics, (20100601), vol. 12, no. 3, ISSN 2040-3445, pages 340 - 349, XP009145639-
OPPOSITION- THAKUR et al., "Cancer therapy with bispecific antibodies: Clinical experience", Current Opinion in Molecular Therapeutics, (20100000), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- VIDAL-LALIENA et al., "Characterization of antibodies submitted to the B-cell section of the 8th human leukocyte differentiation antigens workshop by flow cytometry and immunohistochemistry", Characterization of antibodies submitted to the B- cell section of the 8th human leukocyte differentiation antigens workshop by flow cytometry and immunohistochemistry, (20050912), vol. 236, doi:10.1016/j.cellimm.2005.08.002, pages 6 - 16, XP005197717
OPPOSITION- KUHNS M S,ET AL, "Deconstructing the form and function of the TCR/CD3 complex", Immunity, AMSTERDAM, NL, (20060201), vol. 24, no. 2, doi:10.1016/j.immuni.2006.01.006, ISSN 1074-7613, pages 133 - 139, XP002396082
OPPOSITION- WALLWEBER et al., "The Crystal Structure of A Proliferation-inducing Ligand, APRIL", Journal of Molecular Biology, (20040000), vol. 343, doi:10.1016/j.jmb.2004.08.040, pages 283 - 290, XP004608969
OPPOSITION- Wallweber, H.J.A. Compaan, D.M. Starovasnik, M.A. Hymowitz, S.G., "The Crystal Structure of A Proliferation-inducing Ligand, APRIL", Journal of Molecular Biology, United Kingdom, (20041015), vol. 343, no. 2, doi:10.1016/j.jmb.2004.08.040, ISSN 0022-2836, pages 283 - 290, XP004576830
OPPOSITION- Bossen, C. Schneider, P., "BAFF, APRIL and their receptors: Structure, function and signaling", SEMINARS IN IMMUNOLOGY, US, (20061001), vol. 18, no. 5, doi:10.1016/j.smim.2006.04.006, ISSN 1044-5323, pages 263 - 275, XP005614343
OPPOSITION- Bossen, C. Schneider, P., "BAFF, APRIL and their receptors: Structure, function and signaling", SEMINARS IN IMMUNOLOGY., W.B. SAUNDERS COMPANY, PA., US, US, (20061001), vol. 18, no. 5, doi:10.1016/j.smim.2006.04.006, ISSN 1044-5323, pages 263 - 275, XP005614343
OPPOSITION- Kufer, P. Lutterbuse, R. Baeuerle, P.A., "A revival of bispecific antibodies", TRENDS IN BIOTECHNOLOGY., ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, GB, (20040501), vol. 22, no. 5, doi:10.1016/j.tibtech.2004.03.006, ISSN 0167-7799, pages 238 - 244, XP004504363
OPPOSITION- McPherson, A., "Introduction to protein crystallization", Methods, Academic Press, NL, NL , (20041101), vol. 34, no. 3, doi:10.1016/j.ymeth.2004.03.019, ISSN 1046-2023, pages 254 - 265, XP004528287
OPPOSITION- BODMER J.-L. ET AL., "The molecular architecture of the TNF superfamily", Trends in Biochemical Sciences, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20020101), vol. 27, no. 1, doi:10.1016/S0968-0004(01)01995-8, ISSN 0968-0004, pages 19 - 26, XP002211955
OPPOSITION- BODMER J-L, SCHNEIDER P, TSCHOPP J, "The molecular architecture of the TNF superfamily.", Trends in Biochemical Sciences, AMSTERDAM, NL, (20020101), vol. 27, no. 1, doi:10.1016/S0968-0004(01)01995-8, ISSN 0968-0004, pages 19 - 26, XP002276709
OPPOSITION- F. Pirrone, Roxana E. Iacob, John R. Engen, "Applications of hydrogen/deuterium exchange MS from 2012 to 2014", ANALYTICAL CHEMISTRY, (20150101), vol. 87, doi:10.1021/ac5040242, pages 99 - 118, XP055746626
OPPOSITION- HIPP et al., "A novel BCMA/ CD 3 bispecific T- cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Leukemia, (20170000), vol. 31, doi:10.1038/leu.2016.388, pages 1743 - 1751, XP055547607
OPPOSITION- Hipp et al., "A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo", Leukemia, (2017), vol. 31, pages 1743 - 1751, XP055547607
OPPOSITION- LIU et al., "Ligand-receptor binding revealed by the TNF family member TALL-1", Nature, (20030000), vol. 423, doi:10.1038/nature01543, pages 49 - 56, XP002328536
OPPOSITION- LIU Y, et al, "Ligand-receptor binding revealed by the TNF family member TALL-1.", Nature, London, (20030501), vol. 423, no. 6935, doi:10.1038/nature01543, ISSN 0028-0836, pages 49 - 56, XP002328536
OPPOSITION- DILLON et al., "An APRIL to remember Novel TNF ligands as therapeutic targets", Nat Rev, (20060300), vol. 5, doi:10.1038/NRD1982, pages 235 - 246, XP002663210
OPPOSITION- Dong De; Zheng Lvqin; Lin Jianquan; Zhang Bailing; Zhu Yuwei; Li Ningning; Xie Shuangyu; Wang Yuhang; Gao Ning; Huang Zhiwei, "Structural basis of assembly of the human T cell receptor-CD3 complex", Nature, Nature Publishing Group UK, London, London, (20190828), vol. 573, no. 7775, doi:10.1038/s41586-019-1537-0, ISSN 0028-0836, pages 546 - 552, XP036888200
OPPOSITION- KJER-NIELSEN et al., "Crystal structure of the human T cell receptor CD3 heterodimer complexed to the therapeutic mAb OKT3", Proceedings of the National Academy of Sciences, (20040500), vol. 101, pages 7675 - 7680, XP055329073
OPPOSITION- PATEL D R,ET AL, "Engineering an APRIL-specific B cell maturation antigen", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, (20040416), vol. 279, no. 16, doi:10.1074/jbc.M312316200, ISSN 0021-9258, pages 16727 - 16735, XP002318161
OPPOSITION- PATEL D R,ET AL, "Engineering an APRIL-specific B cell maturation antigen", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (20040416), vol. 279, no. 16, doi:10.1074/jbc.M312316200, ISSN 0021-9258, pages 16727 - 16735, XP002318161
OPPOSITION- PATEL D R,ET AL, "Engineering an APRIL-specific B cell maturation antigen", Journal of Biological Chemistry, US, (20040416), vol. 279, no. 16, doi:10.1074/jbc.M312316200, ISSN 0021-9258, pages 16727 - 16735, XP002318161
OPPOSITION- PATEL et al., "Engineering an APRIL-specific B- Cell Maturation Antigen", Journal of Biological Chemistry, (20040000), vol. 279, no. 16, doi:10.1074/jbc.M312316200, pages 16727 - 16735, XP002318161
OPPOSITION- HYMOWIT Z et al., "Structures of APRIL-Receptor Complexes", Journal of Biological Chemistry, (20050000), vol. 280, no. 8, doi:10.1074/jbc.M411714200, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ et al., "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", J Biol Chem., (20050000), vol. 280, no. 8, pages 7218 - 27, XP002373779
OPPOSITION- HYMOWITZ et al., "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", Journal of Biological Chemistry, (20050200), vol. 280, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ et al., The Journal of Biological Chemistry, (20050000), vol. 280, no. 8, pages 7218 - 7227, XP002373779
OPPOSITION- HYMOWITZ S G, ET AL., "Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding", Journal of Biological Chemistry, US, (20050225), vol. 280, no. 8, doi:10.1074/jbc.M411714200, ISSN 0021-9258, pages 7218 - 7227, XP002373779
OPPOSITION- Kishimoto H, Kubo R T, Yorifuji H, Nakayama T, Asano Y, Tada T, "Physical dissociation of the TCR-CD3 complex accompanies receptor ligation.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (19951201), vol. 182, no. 6, doi:10.1084/jem.182.6.1997, ISSN 0022-1007, pages 1997 - 2006, XP093039006
OPPOSITION- RENNERT P, ET AL, "A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth", The Journal of Experimental Medicine, US, (20001204), vol. 192, no. 11, doi:10.1084/jem.192.11.1677, ISSN 0022-1007, pages 1677 - 1683, XP002224719
OPPOSITION- Syuichi Koarada, Et Al, "Autoantibody-producing RP105 B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects", Rheumatology, (20100122), vol. 49, pages 662 - 670, XP055753149
OPPOSITION- MOREAUX et al., "APRIL and TACl interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop", Eur J Heamatol, (20090000), vol. 83, doi:10.1111/j.1600-0609.2009.01262.x, pages 119 - 129, XP055377292
OPPOSITION- Clifford S Guy, Vignali, Dario, "Organization of proximal signal initiation at the TCR:CD3 complex", Immunol Rev, (20090101), vol. 232, no. 1, pages 7 - 21, XP055753147
OPPOSITION- Kontermann et al., "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, (2005), vol. 26, pages 1 - 9, XP002426874
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- KONTERMANN ROLAND E, "Recombinant bispecific antibodies for cancer therapy", Acta Pharmacologica Sinica, Nature Publishing Group, GB, GB, (20050101), vol. 26, no. 1, doi:10.1111/j.1745-7254.2005.00008.x, ISSN 1671-4083, pages 1 - 9, XP002426874
OPPOSITION- BAEUERLE et al., "Bispecific T-cell engaging antibodies for cancer therapy", Cancer Research, (20090000), vol. 69, no. 12, doi:10.1158/0008-5472.CAN-09-0547, pages 4941 - 4944, XP002665118
OPPOSITION- BAEUERLE PATRICK A , REINHARDT CARSTEN, "Bispecific T-cell engaging antibodies for cancer therapy.", CANCER RESEARCH, US, (20090615), vol. 69, no. 12, doi:10.1158/0008-5472.CAN-09-0547, ISSN 1538-7445, pages 4941 - 4944, XP002665118
OPPOSITION- Panowski et al, "Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma", Molecular cancer therapeutics, (20190821), pages 1 - 13, Molecular cancer therapeutics, (20200728), XP055718531
OPPOSITION- A. J. Novak, "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040115), vol. 103, no. 2, doi:10.1182/blood-2003-06-2043, ISSN 00064971, pages 689 - 694, XP055004448
OPPOSITION- NOVAK et al., "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040000), vol. 103, no. 2, doi:10.1182/blood-2003-06-2043, pages 689 - 694, XP055004448
OPPOSITION- Novak et al., "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival", Blood, (20040115), vol. 103, no. 2, pages 689 - 694, XP055004448
OPPOSITION- Merav Leiba, Et Al, "Activation of b- cell maturation antigen (BCMA) on human multiple myeloma cells by a proliferation-inducing ligand (APRIL) promotes myeloma cell function in the bone marrow microenvironment", Blood, (20070101), vol. 110, no. 11, pages 1503 - 1504, XP055744224
OPPOSITION- BAEUERLE et al., "BiTE: A new class of antibodies that recruit T-cells", Drugs of the Future, (20080000), vol. 33, no. 2, doi:10.1358/DOF.2008.033.02.1172578, pages 137 - 147, XP002667644
OPPOSITION- Choi Bryan D; Cai Mingqing; Bigner Darell D; Mehta Ankit I; Kuan Chien-Tsun; Sampson John H, "Bispecific antibodies engage T cells for antitumor immunotherapy.", Expert opinion on biological therapy, UK, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.572874, ISSN 1744-7682, pages 843 - 853, XP009169599
OPPOSITION- CHOI et al., "Bispecific antibodies engage T-cells for antitumor immunotherapy", Expert Opinion on Biological Therapy, (20110000), vol. 11, no. 7, doi:10.1517/14712598.2011.572874, pages 843 - 853, XP055250825
OPPOSITION- Hager-Braun Christine; Tomer Kenneth B, "Determination of protein-derived epitopes by mass spectrometry.", EXPERT REVIEW OF PROTEOMICS, FUTURE DRUGS, LONDON, GB, GB, (20051001), vol. 2, no. 5, doi:10.1586/14789450.2.5.745, ISSN 1744-8387, pages 745 - 756, XP009182008
OPPOSITION- CHAMES et al., "Bispecific antibodies for cancer therapy. The light at the end of the tunnel?", mAbs, (20091100), vol. 1, pages 539 - 547, XP002688758

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents